Uncategorized

Traders Alert: Targa Resources, Inc. (NYSE:TRGP) & Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Targa Resources, Inc. (NYSE:TRGP)

Targa Resources Corp owns general and limited partner interests in Targa Resources Partners LP, engaged in providing midstream natural gas and natural gas liquid services in the United States. The Company operates its business through two business segments: Natural Gas Gathering and Processing and NGL Logistics and Marketing. The Natural Gas Gathering and Processing segment includes assets used in the gathering of natural gas produced from oil and gas wells and processing this raw natural gas into merchantable natural gas by extracting natural gas liquids and removing impurities. NGL Logistics and Marketing segment is engaged in gathering and storing; fractionating, storing, and transporting of finished NGLs. Targa also markets the natural gas liquids produced and purchased in selected United States markets. The Company also offers refinery services and wholesale propane marketing operations. Targa Resources Corp is headquartered in Houston, Texas.

Targa Resources, Inc. (NYSE:TRGP)’s Financial Overview

Targa Resources, Inc. (NYSE) surged 2.66% yesterday to close its trading session at $43.63. The company has 1 year Price Target of $55.95. Targa Resources, Inc. has 52-Week high of $59.21 and 52-Week Low of $33.55. The stock touched its 52-Week High on 59.21 and 52-Week Low on 33.55. The stock traded with the volume of 1.81 Million shares yesterday. The firm shows the market capitalization of $10.02 Billion.

Targa Resources, Inc. (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.24/share against the analyst consensus estimate of $0.06/share. The difference between the actual and expected EPS is $-0.3 a share with a surprise factor of -500%.

The firm is trading with SMA20 of 1.87 Percent, SMA50 of 4.72 Percent and SMA200 of -11.03 percent. Targa Resources, Inc. has P/S value of 0.95 while its P/B value stands at 1.62. Similarly, the company has Return on Assets of 1.8 percent, Return on Equity of 4.4 percent and Return on Investment of -0.1 Percent. The company shows Gross Margin and Operating Margin of 20.7 percent and 4.1 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 22 analysts offering 12-month price forecasts for Targa Resources Corp have a median target of 55.50, with a high estimate of 70.00 and a low estimate of 43.00. The median estimate represents a +27.21% increase from the last price of 43.63.

Targa Resources, Inc. is expected* to report earnings on 02/20/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 9 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.07. The reported EPS for the same quarter last year was $-0.07.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company’s proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s Financial Outlook

The 6 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 24.25, with a high estimate of 30.00 and a low estimate of 19.00. The median estimate represents a +39.77% increase from the last price of 17.35.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Arrowhead Pharmaceuticals, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 2.54% and closed its last trading session at $17.35. The company has the market capitalization of $1.58 Billion. The stock has 52-week high of $22.39 and 52-Week low of $4.77. The firm touched its 52-Week high on 22.39 and 52-Week low on 4.77. The company has volume of 2.77 Million shares. The company has a total of 91.09 Million shares outstanding.

Arrowhead Pharmaceuticals, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.12/share where the analyst estimated EPS was $-0.12/share. The difference between the actual and Estimated EPS is $0. This shows a surprise factor of 0 percent.

The company has YTD performance of 39.69 percent. Beta for Arrowhead Pharmaceuticals, Inc. stands at 2.13 while its ATR (average true range) is 0.98. The company has Weekly Volatility of 10.28%% and Monthly Volatility of 6.28%%.

Arrowhead Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of 23.26%, Distance from 50-Day Simple Moving Average of 26.04 percent and Distance from 200-Day Simple Moving Average of 25.58%.

The Company currently has ROA (Return on Assets) of -16.9 percent, Return on Equity (ROE) of -24.1 Percent and Return on Investment (ROI) of -57% with Gross margin of 0 percent and Operating & Profit margin of -65.7% and -61.8% respectively.